REG - Craneware plc - Share buyback programme and Total Voting Rights

CranewareAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260316:nRSP6940Wa&default-theme=true

RNS Number : 6940W  Craneware plc  16 March 2026

Craneware plc

("Craneware" or the "Company" or the "Group")

 

Share buyback programme and Total Voting Rights

 

The board of directors of Craneware ("Board") is pleased to announce the
commencement of a share buyback programme to purchase ordinary shares of 1
pence each in the Company ("Ordinary Shares") for an aggregate purchase of up
to $25 million ("Programme"). The Programme follows the intention to undertake
a share buyback programme announced with the Group's FY26 Interim Results.

 

The Board believes that the current market price does not reflect the large
addressable market opportunity of the Group or the strategic position the
Group has within US Healthcare. As a result, the Board considers the share
buyback programme, as part of its capital allocation strategy, to be an
important component of shareholder returns, enhancing return on equity,
increasing earnings per share and offsetting future dilution from existing
employee share incentive schemes.

 

Ordinary Shares acquired under the Programme will be held in treasury to cover
existing share options and long-term incentive plan awards which have been
granted by the Company to employees. Excess Ordinary Shares beyond existing
share options and long-term incentive plan awards will be cancelled.

 

Craneware has entered into agreements with each of Peel Hunt LLP, Investec and
Berenberg to carry out on-market purchases. Peel Hunt, Investec and Berenberg
are each acting independently as riskless principal.

 

The Programme will operate under the authority granted to the Group by
shareholders at the Group's most recent Annual General Meeting, held on 21
November 2025, to acquire a maximum of 3,542,956 Ordinary Shares and will be
effective from the date of this announcement and will expire on the earlier of
(a) 31 December 2026; (b) the conclusion of the next Annual General Meeting of
the Company to be held in 2026; and (c) the maximum aggregate consideration of
$25 million has been reached. It will be conducted in compliance with Article
5(1)(b) of the UK version of Regulation (EU) No. 596/2014 which is part of UK
law by virtue of the European Union (Withdrawal) Act 2018 and the delegated
regulations made pursuant to it.

 

The Company will make further announcements in due course following the
completion of any repurchases as required by UK MAR.

 

Total Voting Rights

 

The Company's issued share capital currently consists of 35,542,169 Ordinary
Shares, of which 28,064 are held in treasury. Accordingly, the total number of
Ordinary Shares in the Company with voting rights is 35,514,105. This figure
may be used by shareholders as the denominator for the calculations by which
they will determine if they are required to notify their interest in, or a
change to their interest in, the Company under the FCA's Disclosure Guidance
and Transparency Rules.

 

For further information, please contact:

 

 Craneware plc                                     +44 (0)131 550 3100
 Keith Neilson, CEO
 Craig Preston, CFO

 Alma Strategic Communications                     +44 (0)20 3405 0205
 Caroline Forde, Kinvara Verdon, Louisa El-Ahwal   craneware@almastrategic.com

 Peel Hunt (NOMAD and Joint Broker)                +44 (0)20 7418 8900
 Neil Patel, Benjamin Cryer, Kate Bannatyne

 Investec Bank PLC (Joint Broker)                  +44 (0)20 7597 5970
 Patrick Robb, Virginia Bull, Arnav Kapoor
 ( )                                               ( )
 Berenberg (Joint Broker)                          +44 (0)20 3207 7800
 Mark Whitmore, Richard Andrews, Patrick Dolaghan

 

About Craneware

 

For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in
healthcare financial and operational transformation, delivering cutting-edge
technologies that drive measurable impact. Our Trisus(®) cloud ecosystem
unifies data, revenue intelligence, margin intelligence, and advanced
analytics, enabling healthcare organizations to optimize performance, improve
financial sustainability, and drive strategic growth. As a trusted Microsoft
partner, we provide future-ready solutions-including the Best in KLAS Trisus
Chargemaster - that simplify the complexities of healthcare finance and
operations. What sets us apart is our unique combination of deep healthcare
expertise and engineering excellence, positioning us as a strategic partner
rather than just a technology provider. The Craneware Group empowers
healthcare organizations to achieve sustainable financial success while
delivering better outcomes for the communities they serve - today and in the
future. Together, we are transforming the business of healthcare.

 

Learn more at www.thecranewaregroup.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCUVAWRNRUOAAR



            Copyright 2019 Regulatory News Service, all rights reserved